FOLH1 and prostate carcinoma: Furthermore, higher SUVmax values exhibit excellent specificity for clinically significant prostate cancer, supporting the use of PSMA uptake as a noninvasive imaging biomarker of tumor biology that complements multiparametric MRI in preoperative risk assessment and treatment planning, with a median PSMA SUVmax of 4 (IQR: 3.4–5.1) when no cancer was found on biopsy, versus 12.3 (IQR: 6.3–15.6) for ISUP grade group 5 malignancy [16].